Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.8K

FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in

Uros Karic1, Ivana Pesic-Pavlovic2, Goran Stevanovic3

  • 1Clinical Centre of Serbia, Belgrade, Serbia. uroskaric@gmail.com.

Journal of Infection in Developing Countries
|December 13, 2019
PubMed

Insights

The Fibrosis-4 Index (FIB-4) accurately identifies patients without severe liver fibrosis in chronic Hepatitis C Virus (HCV) infection. FIB-4 demonstrated superior performance compared to the AST to Platelet Ratio Index (APRI) in this patient group.

Area of Science:

  • Hepatology
  • Virology
  • Medical Diagnostics

Background:

  • Chronic Hepatitis C Virus (HCV) infection causes progressive liver fibrosis, necessitating accurate staging.
  • Non-invasive fibrosis scores are emerging as alternatives to liver biopsy.
  • The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) are widely used non-invasive markers.

Purpose of the Study:

  • To evaluate the accuracy of FIB-4 and APRI scores in identifying patients with chronic HCV infection who are unlikely to have severe fibrosis.
  • To compare the diagnostic performance of FIB-4 and APRI for significant fibrosis detection.

Main Methods:

  • Analysis of 142 patients with chronic HCV infection who underwent liver biopsy.
  • Calculation of FIB-4 and APRI scores for each patient.
  • Comparison of calculated scores with histologically determined fibrosis stages.

Main Results:

  • Patients with non-severe fibrosis were younger, had higher platelet counts, and lower transaminase levels.
  • FIB-4 achieved an Area Under the Curve (AUC) of 0.875, while APRI achieved an AUC of 0.861.
  • FIB-4 demonstrated superior accuracy in identifying severe fibrosis compared to APRI within the study cohort.

Conclusions:

  • FIB-4 is superior to APRI in recognizing severe fibrosis in chronic HCV patients.
  • FIB-4 is a valuable tool for identifying patients without advanced liver disease, particularly when other non-invasive methods are unavailable.
Abstract

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

397

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
454
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
143
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
178